Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 78

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 78
---
 to comply with applicable data protection, privacy and security laws,                                 
 regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition. |

| • |     | Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty                     
 and cost for us to obtain marketing approval for and commercialize our Product Candidates and may affect the prices we may set. |

| • |     | Some of our investments may be subject to review from the Committee on Foreign Investment in the U.S. which 
 may delay or block a transaction from closing.                                                              |

| • |     | If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required 
 to limit commercialization of our products.                                                                    |

| • |     | Our IT Systems, or those of our CROs, manufacturers, other contractors, vendors, consultants or collaborators,                                                                                                                                           
 may fail or suffer system failures, security breaches or deficiencies in cybersecurity, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or trigger contractual 
 and legal obligations.                                                                                                                                                                                                                                   |

| • |     | Our employees and independent contractors, including principal investigators, CROs, consultants and vendors,               
 may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. |

6

| • |     | We may engage in strategic transactions that could impact our liquidity, increase our expenses and present 
 significant distractions to our management.                                                                |

| • |     | Significant changes or developments in U.S. laws or policies, including changes in U.S. trade policies and                                                  
 tariffs and the reaction of other countries thereto, may have a material and adverse effect on our business, financial condition and results of operations. |

Risks Related to Intellectual Property

| • |     | Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our 
 proprietary technologies.                                                                                     |

| • |     | If we fail to comply with our obligations under any license, collaboration or other agreements, or otherwise                                                                                                                                           
 experience disruptions to our business relationships with our collaborators or future licensors, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future 
 Product Candidates.                                                                                                                                                                                                                                    |

| • |     | If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent                                                                   
 protection, our ability to prevent our competitors and other